VALBIOTIS
VALBIOTIS SA
Press release
Valbiotis announces the availability of an amendment
This document is made available to the public free of charge in accordance with applicable regulations and can be accessed and downloaded from Valbiotis' website (www.valbiotis.com/en/regulatory-information/) and the AMF website (www.amf-france.org/).
In addition to the Universal Registration Document filed with the French Financial Markets Authority (AMF) on April 26, 2023, under reference D. 23-0347, this amendment reflects the recently communicated highlights as well as the update following the publication of the half-year financial results on September 28, 2023.
About Valbiotis Valbiotis is a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs. Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic and cardiovascular diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources. Internationally, its products are intended to be the subject of licensing and/or distribution agreements with global or regional health and nutrition players. In France, Valbiotis will be responsible for marketing its own products. Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada). Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company. For more information about Valbiotis, please visit: www.valbiotis.com.
Contacts Corporate communication / Valbiotis Carole ROCHER Communication and Public Affairs Director +33 6 77 82 56 88 media@valbiotis.com
Financial communication / Seitosei Actifin Marianne PY Senior consultant +33 1 80 48 25 31 mpy@actifin.fr
Name: Valbiotis Ticker symbol: ALVAL EnterNext© PEA-PME 150
The present press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, these are in no way guarantees of future performance and may be affected by changes in economic conditions, financial markets, and a number of risks and uncertainties, including those described in Valbiotis' Universal Registration Document filed with the French Financial Markets Authority (AMF) on April 26, 2023, under No. D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under No. D.23-0347.A01. This document is available on the Company's website (www.valbiotis.com). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
Regulatory filing PDF file File: 2023-12-11_PR_VALBIOTIS_URD_AMENDMENT |
| Language: | English |
| Company: | VALBIOTIS SA |
| 12F, Rue Paul Vatine | |
| 17180 Périgny | |
| France | |
| Phone: | 0546286258 |
| E-mail: | contact@valbiotis.com |
| Internet: | www.valbiotis.com |
| ISIN: | FR0013254851 |
| Euronext Ticker: | ALVAL |
| AMF Category: | Inside information / Other releases |
| EQS News ID: | 1794517 |
| End of Announcement | EQS News Service |
1794517 11-Dec-2023 CET/CEST
